Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
FIRALIS S.A. logo — Innovative biomarker solutions for improved diagnostics, enh...

FIRALIS S.A.

Innovative biomarker solutions for improved diagnostics, enhancing patient outcomes and optimizing healthcare costs.

Founded 2008 France France 28 employees Series B Total: $1.93M Biotechnology, Health Care +1

General Information

Company Name FIRALIS S.A.
Founded Year 2008
Location France France +1
Employees 28
Industries Biotechnology, Health Care, Industrial
Funding Stage Series B
Social

Get notified when FIRALIS S.A. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About FIRALIS S.A.

FIRALIS S.A. is a leading biotechnology company based in Basel, Switzerland, specializing in innovative biomarker solutions for enhanced diagnostics, improved patient outcomes, and optimized healthcare costs. Since its establishment in 2008, the company has been at the forefront of biomarker (BM) discovery, development, and qualification, with a focus on cardiovascular, inflammatory, autoimmune, and neurology-related biomarkers. The company's offerings encompass a range of products and services, including RUO Kits (Research-Use-Only) and IVD Tools (In Vitro Diagnostic) that are based on clinically qualified biomarkers. Additionally, Firalis provides biomarker-related CRO services, including proteomics, genomics/transcriptomics, flow cytometry, assay development, biobanking, sample repository services, and data analysis tailored to the specific requirements of laboratories, biotechs, and the pharmaceutical industry. The latest investment of €1.48M in Series B funding received on 04 July 2013 from Auriga Partners and Financiere De l'Echiquier serves as a testament to the confidence that notable investors have in Firalis' innovative approach and its potential to advance the field of biomarker-based diagnostics and personalized medicine. For further insights into their pioneering work, interested parties can visit their website for additional information.

Taxonomy: biomarker development, diagnostic tools, biomarker R&D, drug safety, personalized medicine, biomarker-related CRO services, proteomics, genomics, transcriptomics, flow cytometry, assay development, biobanking, regulatory qualification, precision medicine, Alzheimer's

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 2
Investor Investor
04 Jul 2013
Seed Round •••••• 1 •••• •••• 30 Jun 2010

FIRALIS S.A. Alternatives & Competitors

FIRALIS S.A. vs
Cypher Genomics
Cypher Genomics United States

Unlocking the potential of human genome data through automated interpretation for clinical labs and...

Non Equity Assistance
2 employees
Analytics, Biotechnology
Compare FIRALIS S.A. vs Cypher Genomics
FIRALIS S.A. vs
ARCHIMEDlife Medical Laboratories
ARCHIMEDlife Medical Laboratories Austria

Pioneering faster diagnosis of your patients through advancements in biochemical, biomarker, and gen...

25 employees
Health Care
Compare FIRALIS S.A. vs ARCHIMEDlife Medical Laboratories
FIRALIS S.A. vs
SENSEERA
SENSEERA Israel

Empowering diagnostics and drug development with AI-driven chromatin liquid biopsy

20 employees
Health Care
Compare FIRALIS S.A. vs SENSEERA

FAQ About FIRALIS S.A.

Innovative biomarker solutions for improved diagnostics, enhancing patient outcomes and optimizing healthcare costs.
FIRALIS S.A. was founded in 2008.
FIRALIS S.A. is headquartered in France.
FIRALIS S.A. operates in the following industries: Biotechnology, Health Care, Industrial.
FIRALIS S.A. has approximately 28 employees.
FIRALIS S.A. has completed 2 funding rounds, raising a total of $1.93M. The latest funding stage is Series B.
Top alternatives and competitors to FIRALIS S.A. include Cypher Genomics, ARCHIMEDlife Medical Laboratories, SENSEERA, SBH Sciences, PBL Assay Science. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FIRALIS S.A. and Cypher Genomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors FIRALIS S.A. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes